On January 25, 2026, Kangnuo Biotech submitted an application for a main board listing on the Hong Kong Stock Exchange.
Driven by "AI + synthetic biology"technologies, the company focuses on the R&D, pharmaceutical manufacturing and commercialization of mitochondrial medicine and health products.
Its core technologies center on the fields of mitochondria and NAD+, and it is committed to the scientific research of NAD+ applications in cardiovascular diseases, neurodegenerative diseases, reproductive health, aging and other areas. The company has established a commercial application system covering NAD+ series active pharmaceutical ingredients (APIs) to NAD+ health consumer products, striving to extend the healthspan of all humans.
In recent years, with the intensification of population aging, anti-aging has emerged as a booming new track, and emerging ingredients acting on cellular energy metabolism and repair pathways such as ergothioneine and NAD+ have attracted widespread attention.
NAD+, or Nicotinamide Adenine Dinucleotide (Coenzyme I), is a coenzyme existing in human cells. It is a key molecule for maintaining mitochondrial function and a biological link between aging and various diseases.
At present, Kangnuo Biotech has 20 pharmaceuticals in production, including four core products: ''En'edi® (Coenzyme I for Injection)", "Qianrongmei® (Hyaluronidase for Injection)", "Tianshu® (Kallidinogenase for Injection)"and Sodium Nitroprusside for Injection.
Among them, En'edi® (Coenzyme I for Injection) is the core product of Kangnuo Biotech. As an NAD+ therapeutic drug independently developed in China and the only one approved for marketing both domestically and globally, its successful commercialization has established Kangnuo Biotech's leading position in the global mitochondrial pharmaceutical industry.
Overview of En'edi Image Source:
Yaozhi Data - Global Pharmaceutical Analysis System
Kangnuo Biotech also markets an additional 16 generic drugs, covering four major therapeutic areas: the digestive system, respiratory system, hematological system and nervous system. For the full year of 2023, 2024 and the first nine months of 2025, Kangnuo Biotech recorded revenues of RMB 303 million, RMB 240 million and RMB 238 million respectively, with net profits of RMB 79.52 million, RMB 33.91 million and RMB 53.41 million in the corresponding periods. Kangnuo Biotech's subsequent R&D pipeline is centered on mitochondrial medicine, with 12 drug candidates in the pipeline at present.
Among them, KN-19ND-L1 and KN-25ND-L1, targeting heart failure and ovarian dysfunction respectively, have both entered Phase II clinical trials, while the remaining drug candidates are in the preclinical stage.
Looking ahead, Kangnuo Biotech stated that it will deepen the market penetration of En'edi, expand its indication scope, and advance the commercialization of subsequent pipeline assets to sustainably drive growth. Through a diversified portfolio of mitochondria-targeted pharmaceutical products, the company will consolidate and strengthen its market competitiveness.
References
1. Prospectus of Kangnuo Biotech
2. https://mp.weixin.qq.com/s/2Hbmj5b738fknEtqHepNAA
3. Yaozhi Data
